Novacap acquires PCI Synthesis to expand offering in the US

By Melissa Fassbender contact

- Last updated on GMT

Novacap acquires PCI Synthesis to expand offering in the US
France-based Novacap is set to acquire PCI Synthesis – a CDMO located near Boston’s biotech hub – to expand its pharmaceutical offerings in the US.

Following the transaction, terms of which were not disclosed, the contract development and manufacturing organization (CDMO) PCI Synthesis will become a wholly owned subsidiary of Novacap.

PCI’s existing management have signed long-term contracts and will remain in place.

“The acquisition of PCI Synthesis perfectly fits with our strategic roadmap as it will strengthen our offering to the pharmaceutical industry and provide Novacap with a strong and innovative platform to accelerate our development in the US,”​ said Pierre Luzeau, CEO of Novacap in a press release.

“The two companies operate complementary CDMO activities and share common values such as entrepreneurship, operational excellence and dedication to customer satisfaction,”​ he added.

Ed Price, founder and president of PCI Synthesis said in a blog post on the company’s website​ that the Boston-based CDMO will be the lead US company for Novacap.

With the acquisition, Price said it is creating a CDMO which can offer a range of services with access to Novacap’s PCAS facilities in France and its Uetikon facility in Germany.

PCI also will have access to Novacap’s “additional chemistry expertise, solid state chemistry development, dual site processing, and substantial additional capacity for the commercialization of the next generation of Life Science products,” ​he said.

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars